Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Terazosin Hydrochloride

FDA-approved product (tablet, oral), marketed as Hytrin, Terazosin Hydrochloride, Tezruly.

Registered studies
41
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Terazosin Hydrochloride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Benign prostatic hyperplasia

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Alpha-adrenoreceptor antagonists
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA, E. coli and K. pneumoniae. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA65.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli60.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae40.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis52.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

41registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Terazosin Hydrochloride in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.0 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-6.7 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.0 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.5 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Terazosin Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Pilot Study of Terazosin for Parkinson's Disease

    NCT03905811 · start 2019-09-24

    Registered record
    Registry ID
    NCT03905811
    Conditions
    Parkinson Disease
    Interventions
    Terazosin 5 MG; Placebo oral capsule
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2019-09-24
    Completion
    2020-11-18
    Enrolment
    13

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionParkinson Disease
    InterventionTerazosin 5 MG; Placebo oral capsule
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Deflox Tablets Bioequivalence (BE) Trial

    NCT04132583 · start 2019-09-21

    Registered record
    Registry ID
    NCT04132583
    Conditions
    Healthy
    Interventions
    Deflox®; Cataflam DD®
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2019-09-21
    Completion
    2019-10-27
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionDeflox®; Cataflam DD®
    PhasePhase 1
    Registry statusCompleted

  • Adrenal Artery Ablation for Primary Aldosteronism

    NCT03653845 · start 2018-07-01

    Registered record
    Registry ID
    NCT03653845
    Conditions
    Primary Aldosteronism; Hypertension
    Interventions
    Endovascular chemical Ablation of Adrenal Gland; Sequenced antihypertensvie drugs with titrated dosage
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2018-07-01
    Completion
    2020-01-01
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPrimary Aldosteronism; Hypertension
    InterventionEndovascular chemical Ablation of Adrenal Gland; Sequenced antihypertensvie drugs with titrated dosage
    PhasePhase 3
    Registry statusUnknown

  • A Randomized Controlled Trial of Doxazosin for Nightmares, Sleep Disturbance, and Non-Nightmare Clinical Symptoms in PTSD

    NCT03339258 · start 2018-04-15

    Registered record
    Registry ID
    NCT03339258
    Conditions
    Stress Disorders, Post-Traumatic
    Interventions
    Doxazosin Mesylate, Extended Release; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2018-04-15
    Completion
    2024-06
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionStress Disorders, Post-Traumatic
    InterventionDoxazosin Mesylate, Extended Release; Placebo
    PhasePhase 2
    Registry statusUnknown

  • Safety and Efficacy of Low Dosage of Terazosin in Subjects Undergoing Carotid Artery Stenting

    NCT03195673 · start 2018-03-02

    Registered record
    Registry ID
    NCT03195673
    Conditions
    Carotid Artery Stenosis
    Interventions
    Terazosin; Carotid artery stenting
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2018-03-02
    Completion
    2019-12-15
    Enrolment
    160

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCarotid Artery Stenosis
    InterventionTerazosin; Carotid artery stenting
    PhasePhase 2
    Registry statusUnknown

  • Rituximab Combined With MSCs in the Treatment of PNS (3-4 Stage of CKD)

    NCT02966717 · start 2016-08

    Registered record
    Registry ID
    NCT02966717
    Conditions
    Renal Insufficiency, Chronic; Nephrotic Syndrome
    Interventions
    Rituximab; conventional therapy; Mesenchymal stem cells
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2016-08
    Completion
    2021-10
    Enrolment
    116

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRenal Insufficiency, Chronic; Nephrotic Syndrome
    InterventionRituximab; conventional therapy; Mesenchymal stem cells
    PhasePhase 2
    Registry statusUnknown

  • Diesel Exhaust and Vascular Function

    NCT01508637 · start 2012-01

    Registered record
    Registry ID
    NCT01508637
    Conditions
    Cardiovascular Effects
    Interventions
    Diesel Exhaust; Filtered Air; Terazosin; placebo
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2012-01
    Completion
    2015-12
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCardiovascular Effects
    InterventionDiesel Exhaust; Filtered Air; Terazosin; placebo
    PhaseNot applicable
    Registry statusUnknown

  • The Effect of Terazosin and Tolterodine on Ureteral Stent Related Symptoms

    NCT01530243 · start 2012-01

    Registered record
    Registry ID
    NCT01530243
    Conditions
    Disorder of Urinary Stent
    Interventions
    Placebo; Terazosine; Tolterodine; Tolterodine + Terazosin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2012-01
    Completion
    2012-09
    Enrolment
    104

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDisorder of Urinary Stent
    InterventionPlacebo; Terazosine; Tolterodine; Tolterodine + Terazosin
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Effect of Renin-angiotensin-system Blockade on Urinary Free Light Chains in Patients With Type 2 Diabetes Mellitus

    NCT02046395 · start 2012-01

    Registered record
    Registry ID
    NCT02046395
    Conditions
    Type 2 Diabetes; Hypertension
    Interventions
    amlodipine, hydralazine, terazosin or hydrochlorothiazide
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2012-01
    Completion
    2019-12
    Enrolment
    28

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionType 2 Diabetes; Hypertension
    Interventionamlodipine, hydralazine, terazosin or hydrochlorothiazide
    PhasePhase 4
    Registry statusCompleted

  • A Pharmacodynamic Study of Dapoxetine Concomitantly Administered in Participants Taking Terazosin

    NCT01366664 · start 2011-04

    Registered record
    Registry ID
    NCT01366664
    Conditions
    Ejaculation
    Interventions
    Treatment sequence 2; Treatment sequence 1
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2011-04
    Completion
    2012-04
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEjaculation
    InterventionTreatment sequence 2; Treatment sequence 1
    PhasePhase 1
    Registry statusCompleted

  • Evaluating the Impact of Early Versus Delayed 5 Alpha Reductase Inhibitor Treatment on the Risk of Emergent Surgery in Men With Benign Prostatic Hyperplasia

    NCT01332487 · start 2010-08

    Registered record
    Registry ID
    NCT01332487
    Conditions
    Prostatic Hyperplasia
    Interventions
    5ARI + AB
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2010-08
    Completion
    2010-08
    Enrolment
    4,068

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstatic Hyperplasia
    Intervention5ARI + AB
    PhaseNot recorded
    Registry statusCompleted

  • Clinical Progression and Costs in Benign Prostatic Hyperplasia Patients Treated With Early Versus Delayed Combination Therapy

    NCT01435954 · start 2010-08

    Registered record
    Registry ID
    NCT01435954
    Conditions
    Benign Prostatic Hyperplasia
    Interventions
    Early combination therapy; Delayed combination therapy
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2010-08
    Completion
    2011-03
    Enrolment
    13,551

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBenign Prostatic Hyperplasia
    InterventionEarly combination therapy; Delayed combination therapy
    PhaseNot recorded
    Registry statusCompleted

  • Benign Prostatic Hypertrophy Treatment Patterns & Outcomes: Marketscan

    NCT01323998 · start 2010-04

    Registered record
    Registry ID
    NCT01323998
    Conditions
    Prostatic Hyperplasia
    Interventions
    5ARI; AB
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2010-04
    Completion
    2010-06
    Enrolment
    35,032

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstatic Hyperplasia
    Intervention5ARI; AB
    PhaseNot recorded
    Registry statusCompleted

  • Atrial Substrate Modification With Aggressive Blood Pressure Lowering to Prevent AF

    NCT00438113 · start 2009-12

    Registered record
    Registry ID
    NCT00438113
    Conditions
    Atrial Fibrillation
    Interventions
    Aggressive Blood Pressure control
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2009-12
    Completion
    2016-09
    Enrolment
    184

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAtrial Fibrillation
    InterventionAggressive Blood Pressure control
    PhasePhase 4
    Registry statusCompleted

  • Dutasteride in Enlarged Prostate Economic Assessment: A Retrospective Database Pooled Analysis of Early 5-alpha Reductase Inhibitor Use

    NCT01332435 · start 2009-11

    Registered record
    Registry ID
    NCT01332435
    Conditions
    Prostatic Hyperplasia
    Interventions
    5ARI + AB
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2009-11
    Completion
    2010-01
    Enrolment
    6,896

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionProstatic Hyperplasia
    Intervention5ARI + AB
    PhaseNot recorded
    Registry statusCompleted